Coherent Price Target Increased to $84.00 by Analysts at Stifel Nicolaus (COHR)
Equities research analysts at Stifel Nicolaus lifted their price objective on shares of Coherent (NASDAQ:COHR) from $74.00 to $84.00 in a research note issued to investors on Monday, ARN reports. The firm currently has a “buy” rating on the stock. Stifel Nicolaus’ price objective would indicate a potential upside of 15.19% from the company’s current price.
Shares of Coherent (NASDAQ:COHR) opened at 72.92 on Monday. Coherent has a 52-week low of $49.73 and a 52-week high of $74.72. The stock has a 50-day moving average of $70.18 and a 200-day moving average of $62.6. The company has a market cap of $1.810 billion and a price-to-earnings ratio of 26.67.
Coherent (NASDAQ:COHR) last released its earnings data on Wednesday, October 30th. The company reported $1.03 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.87 by $0.16. The company had revenue of $213.10 million for the quarter, compared to the consensus estimate of $207.34 million. During the same quarter in the prior year, the company posted $0.71 earnings per share. The company’s quarterly revenue was up 12.9% on a year-over-year basis. On average, analysts predict that Coherent will post $3.96 earnings per share for the current fiscal year.
A number of other analysts have also recently weighed in on COHR. Analysts at Noble Financial raised their price target on shares of Coherent from $65.00 to $72.00 in a research note to investors on Friday, November 1st. They now have a “buy” rating on the stock. Analysts at Needham & Company raised their price target on shares of Coherent from $65.00 to $70.00 in a research note to investors on Friday, November 1st. They now have a “buy” rating on the stock. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $75.33.
Coherent, Inc (NASDAQ:COHR) is a suppliers of photonics-based solutions in a range of commercial and scientific research applications.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.